Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $44.56.

BCYC has been the subject of a number of analyst reports. B. Riley lowered Bicycle Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $33.00 to $28.00 in a report on Wednesday, August 7th. Royal Bank of Canada assumed coverage on Bicycle Therapeutics in a research note on Friday, September 6th. They set an “outperform” rating and a $35.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Finally, Oppenheimer restated an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, August 7th.

Bicycle Therapeutics Stock Performance

BCYC stock opened at $27.02 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. Bicycle Therapeutics has a 1-year low of $12.54 and a 1-year high of $28.20. The business has a 50-day moving average price of $22.93 and a 200 day moving average price of $23.03. The company has a market capitalization of $1.28 billion, a P/E ratio of -6.07 and a beta of 0.90.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.33. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. The business had revenue of $9.36 million during the quarter, compared to analyst estimates of $6.13 million. The company’s quarterly revenue was down 17.9% on a year-over-year basis. As a group, equities research analysts forecast that Bicycle Therapeutics will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Kevin Lee sold 3,194 shares of the business’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $19.64, for a total transaction of $62,730.16. Following the sale, the chief executive officer now directly owns 384,076 shares of the company’s stock, valued at $7,543,252.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 4,555 shares of company stock worth $89,460 in the last three months. Corporate insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its position in Bicycle Therapeutics by 45.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock worth $10,001,000 after purchasing an additional 124,809 shares during the period. Trexquant Investment LP grew its holdings in Bicycle Therapeutics by 177.6% during the fourth quarter. Trexquant Investment LP now owns 196,323 shares of the company’s stock worth $3,550,000 after acquiring an additional 125,604 shares during the period. Parkman Healthcare Partners LLC raised its position in Bicycle Therapeutics by 155.0% during the fourth quarter. Parkman Healthcare Partners LLC now owns 312,889 shares of the company’s stock valued at $5,657,000 after acquiring an additional 190,168 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after acquiring an additional 121,613 shares during the period. Finally, TD Asset Management Inc boosted its position in Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after purchasing an additional 42,200 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.